(Q43664402)

English

SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction

scientific article published in June 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction (English)

1 reference

Europe PubMed Central

25 November 2017

0 references

Parkinson's disease

1 reference

based on heuristic

inferred from title

Mitsuharu Yoshiyama

4

1 reference

Europe PubMed Central

25 November 2017

author name string

Sakakibara R

1

1 reference

Europe PubMed Central

25 November 2017

Shinotoh H

2

1 reference

Europe PubMed Central

25 November 2017

Uchiyama T

3

1 reference

Europe PubMed Central

25 November 2017

Hattori T

5

1 reference

Europe PubMed Central

25 November 2017

Yamanishi T

6

1 reference

Europe PubMed Central

25 November 2017

publication date

1 June 2001

1 reference

Europe PubMed Central

25 November 2017

Journal of the Neurological Sciences

1 reference

Europe PubMed Central

25 November 2017

187

1 reference

Europe PubMed Central

25 November 2017

1-2

1 reference

Europe PubMed Central

25 November 2017

55-59

1 reference

Europe PubMed Central

25 November 2017

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

[123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

In vivo binding of [125I]RTI-55 to dopamine transporters: pharmacology and regional distribution with autoradiography

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Effects of apomorphine and L-dopa on the parkinsonian bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Extrapyramidal inhibition of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Lower urinary tract dysfunction in Parkinson's disease: changes relate to age not disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Criteria for diagnosing Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

The presymptomatic period in a patient with idiopathic parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Urinary function in elderly people with and without leukoaraiosis: relation to cognitive and gait function

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Neural control of the lower urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Voiding and MRI analysis of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Disturbances of micturition in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900521-4

7 January 2021

Identifiers

10.1016/S0022-510X(01)00521-4

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43664402&oldid=2104530775"